News

Applied Clinical Trials Online3h
DESTINY-Breast11 Trial Shows Enhertu Plus THP Significantly Improves Response Rates in High-Risk HER2-Positive Early Breast Cancer
Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...
Applied Clinical Trials Online22h
Nanobiotix Shares Positive Data from MD Anderson-Led Phase I Study in Pancreatic Cancer
JNJ-1900 (NBTXR3), a novel, potentially first-in-class oncology therapy, demonstrated a median overall survival of 23 months ...